Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Novacyt ( (FR:ALNOV) ).
Novacyt has launched the LightBench® Discover, a high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing. Developed in collaboration with PacBio®, the LightBench® Discover integrates functions that replace multiple instruments, offering cost-effective, high-performance solutions for large fragment analytics and DNA size selection. This launch is expected to enhance Novacyt’s market position in genomic research by strengthening partnerships and improving operational efficiency.
More about Novacyt
Novacyt is an international molecular diagnostics company that offers a broad portfolio of integrated technologies and services, focusing on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation, providing end-to-end solutions across sectors such as human health, animal health, and environmental. Novacyt operates in three business segments: Clinical, Instrumentation, and Research Use Only, and is headquartered in Le Vésinet, France, with offices in the UK, Singapore, the US, and Canada. It is listed on the London Stock Exchange’s AIM market and the Paris Stock Exchange Euronext Growth.
For a thorough assessment of ALNOV stock, go to TipRanks’ Stock Analysis page.